Hepatitis C Heavyweights: Schering-Plough and Roche are Slugging it Out for Dominance in a Billion-dollar Market

Author：  

Publisher： Adis International

ISSN： 1537-1328

Source： Pharmaceutical Innovation, Vol.11, Iss.3, 2002-04, pp. : 34-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Schering-Plough Canada finds defect in Pegetron cartridges

By  

Reactions Weekly, Vol. 1, Iss. 1324, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Peginterferon-α-2b [Pegintron; Schering-Plough] has been approved by the Chinese State Food and Drug Administration for chronic hepatitis B;

By  

Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

One-half of the new prescription share for Schering-Plough's loratadine product [`Claritin']

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 373, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

A 23% market share of new prescriptions for hepatitis C in the US has been captured by Roche's antiviral agent PEG-interferon (IFN)- -2a

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 402, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite